Detection of benzo[a]pyrene-diol-epoxide-DNA adducts in white blood cells of psoriatic patients treated with coal tar.
An enzyme-linked immunosorbent assay (ELISA) was used to detect BPDE-DNA adducts in white blood cells of 23 psoriatic patients undergoing clinical coal tar therapy. Ten of these patients were reanalyzed 2-5 months after the end of the coal tar treatments. The results show that the mean adduct level during the treatment period was 0.26 +/- 0.16 fmole BPDE/micrograms DNA (7.7 +/- 4.9 adducts/10(8) nucleotides), while 2-5 months later the mean adduct level had decreased significantly (P less than 0.005) to 0.11 +/- 0.08 fmole BPDE/micrograms DNA (3.3 +/- 2.4 adducts/10(8) nucleotides). No relationship could be ascertained between the level of exposure and the amount of BPDE-DNA adducts. In addition, no difference in the level of DNA adducts was found between smoking and non-smoking patients.
Department of Biology, University of Padua, Italy.
M
M
Paleologo
F J
FJ
van Schooten
S
S
Pavanello
E
E
Kriek
M
M
Zordan
E
E
Clonfero
C
C
Bezze
A G
AG
Levis
D000328:Adult; D000704:Analysis of Variance; D001564:Benzo(a)pyrene / Q000378:metabolism*; D003033:Coal Tar / Q000494:pharmacology*; D004247:DNA / Q000378:metabolism*; D018736:DNA Adducts; D004249:DNA Damage; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005500:Follow-Up Studies; D006801:Humans; D007962:Leukocytes / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000235:genetics; D015203:Reproducibility of Results; D012907:Smoking / Q000009:adverse effects
D018736:DNA Adducts; C056612:benzo(a)pyrene-DNA adduct; D001564:Benzo(a)pyrene; D003033:Coal Tar; D004247:DNA